E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Atopic dermatitis (atopic eczema) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To evaluate the short-term safety and tolerability of 2 formulations of 1% pimecrolimus ointment when applied twice a day for 2 weeks on the lesional skin of patients with moderate to severe atopic dermatitis (AD). •To measure the blood concentrations and pharmacokinetics of 2 formulations of 1% pimecrolimus ointment when applied twice a day for 2 weeks on a relevant extent of lesional skin (at least 30% of the total body surface area) in patients with moderate to severe AD.
|
|
E.2.2 | Secondary objectives of the trial |
•To explore the efficacy of 2 formulations of 1% pimecrolimus ointment applied topically on the lesional skin of patients with moderate to severe AD. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Male and/or female patients with AD from 18-45 years of age.
2.Female subjects must have been surgically sterilized at least 6 months prior to screening. Female subjects of child bearing potential must be using a double-barrier local contraception, i.e. intra-uterine device plus condom, or spermicidal gel plus condom. Postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion.
3.Subjects must fulfill the diagnostic criteria of Hanifin and Rajka for AD.
4.The severity of AD must be defined as moderate or severe by using the Investigator’s Global Assessment. The IGA score will be ≥3 and ≤4. The extent of the disease will be determined by the rule of nine. AD must involve at least 30% of the subject’s body surface area.
5.Vital signs (after 3 minutes resting measured in the supine position) which are within the following ranges: oral body temperature between 35.0-37.5 °C systolic blood pressure, 90-140 mm Hg diastolic blood pressure, 50-90 mm Hg pulse rate, 40 - 90 bpm
6.Subject able to provide written informed consent prior to study participation.
7.Subjects able to communicate well with the investigator and comply with the requirements of the study.
|
|
E.4 | Principal exclusion criteria |
1.Patients with very severe AD (IGA≥5), Netherton’s syndrome or psoriasis. 2.Clinically significant findings except AD during the physical examination or laboratory abnormalities. 3.Symptoms of a significant clinical illness other than AD in the three-week period preceding the entry in the study. 4.Presence of any viral or fungal or untreated bacterial skin infection. 5.History of clinically significant drug allergy especially subjects with known serious adverse reactions or hypersensitivity to macrolides or with known hypersensitivity to any of the ingredients of the study medication. 6.Women who are pregnant or breast feeding and women who do not use double barrier contraception during and at least until 4 weeks after the end of treatment. 7.Use of any prescription drug or over-the-counter (OTC) medication within 2 weeks prior to dosing. Paracetamol is acceptable, but must be documented. 8.History of presence of malignancy, including skin cancer, or lymphoproliferative disorder. 9.Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. 10.Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing. 11.History of autonomic dysfunction. 12.Use of systemic corticosteroids (i.e. oral, intravenous, intra-articular, rectal) within four (4) weeks prior to baseline. Phototherapy within four (4) weeks prior to baseline. Topical therapy (e.g. tar, topical corticosteroids, topical anti-fungals,) within 3 days prior to baseline, with the exception of emollients. Topical tacrolimus within 2 weeks prior to baseline. 13.Treatment with nephrotoxic drugs within two (2) weeks to baseline (aminoglycosides, amphotericin B, colchicine). 14.Treatment with any CYP3A4 inhibitors or inducers within two (2) weeks prior to baseline and during the study course (i.e. azole antifungals, macrolide antibiotics, dexamethasone, phenytoin, ritonavir, rifabutin, antiepileptic agents/barbiturates, cimetidine, St. John’s wort, etc.) 15.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study. The investigator should be guided by evidence of any of the following: • clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin. SGPT will have to be strictly within the normal range before inclusion, GGT and alkaline phosphatase must not exceed twice the upper limit of the normal range, and serum bilirubin should not exceed the value of 27 µmol/L (1.6 mg/dL). • history or presence of impaired renal function as indicated by abnormal creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria); • polymorphonuclears <1500/µL or platelets <100’000/µL at inclusion. 16.History of immunocompromise, including a positive HIV (ELISA and Western blot) test result. 17.A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. 18.History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The endpoints include pharmacokinetic endpoints to measure drug levels in patients, as well as safety/tolerability assessments. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Information not present in EudraCT |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Two formulations with the same active ingredient will be compared in the trial |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 7 |